Valneva Received MHRA’s Conditional Marketing Authorization for its Inactivated COVID-19 Vaccine
Shots:
- UK’s MHRA has granted CMA to Valneva’s VLA2001 for primary immunization in adults aged 18-50yrs
- The CMA is based on the results that showed VLA2001 meets the required safety, quality and effectiveness standards. The CMA followed EUA which was granted by the Bahraini NHRA in Mar’22
- VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in the EU. The company is currently in discussion with the Scottish government to supply ~25,000 doses to the National Health Service and frontline workers in Scotland
Ref: Valneva | Image: Valneva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
